Evidence map›Paper›PMID 36811327›Full record

Trial reportPharmacology research & perspectives2023

Clinical effect of different doses of ciprofol for induction of general anesthesia in elderly patients: A randomized, controlled trial.

Gongchen Duan, Haiyan Lan, Weifeng Shan, Yini Wu, Qiaomin Xu, Xiaoli Dong, Peiyi Mei, Minji You, Linfei Jin, Jimin Wu

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmacology research & perspectives, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 4 pooled it
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Estimation of EDDrug design, development and therapy · 2025
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Gongchen DuanDepartment of Anesthesiology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.ORCID 0000-0001-6680-3031
Haiyan LanDepartment of Anesthesiology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.ORCID 0000-0002-2343-7817
Weifeng ShanDepartment of Anesthesiology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Yini WuDepartment of Anesthesiology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Qiaomin XuDepartment of Anesthesiology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Xiaoli DongDepartment of Anesthesiology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Peiyi MeiDepartment of Anesthesiology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Minji YouDepartment of Anesthesiology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Linfei JinDepartment of Anesthesiology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Jimin WuDepartment of Anesthesiology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.ORCID 0000-0002-0979-1115
Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ciprofol is a newly developed intravenous anesthetic agent with improved pharmacokinetic properties. Compared to propofol, ciprofol exhibits stronger binding to the GABAA receptor and elicits a greater enhancement of GABAA receptor-mediated neuronal currents in vitro. The aims of the present clinical trials were to examine the safety and efficacy of different doses of ciprofol for induction of general anesthesia in elderly patients. A total of 105 elderly patients undergoing elective surgery were randomized, in a 1:1:1 ratio, to receive one of three sedation regimens: (1) the C1 group (0.2 mg/kg ciprofol), (2) the C2 group (0.3 mg/kg ciprofol), (3) the C3 group (0.4 mg/kg ciprofol). The primary outcome was the incidence of various adverse events, including hypotension, hypertension, bradycardia, tachycardia, hypoxemia, and injection pain. The secondary outcomes of efficacy were the success rate of general anesthesia induction, the time to anesthesia induction, and the frequency of remedial sedation was recorded in each group. Adverse events occurred in 13 patients (37%) in group C1, 8 patients (22%) in group C2, and 24 patients (68%) in group C3. Compared with group C2, the total incidence of adverse events was significantly higher in group C1 and group C3 (p < .001).The success rate of general anesthesia induction in the three groups was 100%. Compared with group C1, the frequency of remedial sedation was significantly lower in group C2 and group C3. The outcomes demonstrated that ciprofol at a dose of 0.3 mg/kg has good safety and efficacy in the induction of general anesthesia in elderly patients. Overall, ciprofol is a new and viable option for the induction of general anesthesia in elderly patients undergoing elective surgery.

Indexed as

HypotensionPropofolAgedAnesthesia, GeneralAnesthetics, IntravenousHumansReceptors, GABA-AAnesthetics, IntravenousPropofolReceptors, GABA-Aciprofoldifferent doseselderly patientshemodynamicsinduction of general anesthesia

Identifiers

PMID36811327
PMCPMC9944862
OpenAlexW4321494771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.